China Pharma Holdings Inc
CPHI1.305USD
-0.015-1.14%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
6.55MMarket Cap
LossP/E TTM
More Details of China Pharma Holdings Inc Company
China Pharma Holdings Inc is a company principally engaged in the development, manufacture and marketing of pharmaceutical products. The Company's products are for human use in connection, and with a variety of high-incidence and high-mortality diseases and medical conditions prevalent. The Company manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. In addition, the Company is also engaged in the production of comprehensive healthcare products and protective products.
China Pharma Holdings Inc Info
Ticker SymbolCPHI
Company nameChina Pharma Holdings Inc
IPO dateFeb 15, 2000
CEOLi (Zhilin)
Number of employees224
Security typeOrdinary Share
Fiscal year-endFeb 15
Address2nd Floor, No. 17, Jinpan Road
CityHAIKOU
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryChina
Postal code570216
Phone8689866811730
Websitehttp://www.chinapharmaholdings.com
Ticker SymbolCPHI
IPO dateFeb 15, 2000
CEOLi (Zhilin)
Company Executives of China Pharma Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Zhilin Li
Ms. Zhilin Li
Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer
Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer
302.76K
--
Ms. Heung Mei Tsui
Ms. Heung Mei Tsui
Director
Director
18.63K
+0.01%
Mr. Gene Michael Bennett
Mr. Gene Michael Bennett
Independent Director
Independent Director
--
--
Mr. Baowen Dong
Mr. Baowen Dong
Independent Director
Independent Director
--
--
Yingwen Zhang
Yingwen Zhang
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Zhilin Li
Ms. Zhilin Li
Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer
Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer
302.76K
--
Ms. Heung Mei Tsui
Ms. Heung Mei Tsui
Director
Director
18.63K
+0.01%
Mr. Gene Michael Bennett
Mr. Gene Michael Bennett
Independent Director
Independent Director
--
--
Mr. Baowen Dong
Mr. Baowen Dong
Independent Director
Independent Director
--
--
Yingwen Zhang
Yingwen Zhang
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
By BusinessUSD
Name
Revenue
Proportion
Domestic Pharmaceuticals
1.03M
0.00%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Domestic Pharmaceuticals
1.03M
0.00%
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Yang (Yan)
8.96%
Zhan (Wenlong)
8.16%
Jianying (Cai)
7.96%
Lai (Kui)
7.96%
Lihua (Li)
7.96%
Other
58.98%
Shareholders
Shareholders
Proportion
Yang (Yan)
8.96%
Zhan (Wenlong)
8.16%
Jianying (Cai)
7.96%
Lai (Kui)
7.96%
Lihua (Li)
7.96%
Other
58.98%
Shareholder Types
Shareholders
Proportion
Individual Investor
53.39%
Hedge Fund
0.82%
Investment Advisor
0.38%
Other
45.41%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
15
76.44K
2.51%
--
2025Q3
15
76.44K
3.87%
-42.24K
2025Q2
15
118.68K
1.40%
+84.90K
2025Q1
14
33.79K
0.88%
+5.19K
2024Q4
14
17.38K
1.34%
+13.31K
2024Q3
13
4.07K
1.47%
-1.93K
2024Q2
13
6.00K
1.31%
-5.59K
2024Q1
11
11.59K
0.89%
-1.57K
2023Q4
12
12.24K
0.98%
+6.13K
2023Q3
12
6.11K
1.50%
+3.00K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Li (Zhilin)
302.76K
9.28%
--
--
Mar 24, 2025
Liu (Tao Chengdu)
300.00K
9.2%
--
--
Mar 24, 2025
Citadel Advisors LLC
23.07K
0.71%
+17.76K
+334.79%
Jun 30, 2025
UBS Financial Services, Inc.
71.23K
2.18%
+60.78K
+581.79%
Jun 30, 2025
Tsui (Heung Mei)
18.63K
0.57%
--
--
Mar 24, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Apr 04, 2025
Merger
10→1
Dec 20, 2023
Merger
5→1
Dec 20, 2023
Merger
5→1
Dec 20, 2023
Merger
5→1
Dec 20, 2023
Merger
5→1
Feb 24, 2023
Merger
10→1
Date
Type
Ratio
Apr 04, 2025
Merger
10→1
Dec 20, 2023
Merger
5→1
Dec 20, 2023
Merger
5→1
Dec 20, 2023
Merger
5→1
Dec 20, 2023
Merger
5→1
Feb 24, 2023
Merger
10→1
Feb 24, 2023
Merger
10→1
Feb 24, 2023
Merger
10→1
Feb 24, 2023
Merger
10→1
FAQs
Who are the top five shareholders of China Pharma Holdings Inc?
The top five shareholders of China Pharma Holdings Inc are:
Li (Zhilin) holds 302.76K shares, accounting for 9.28% of the total shares.
Liu (Tao Chengdu) holds 300.00K shares, accounting for 9.20% of the total shares.
Citadel Advisors LLC holds 23.07K shares, accounting for 0.71% of the total shares.
UBS Financial Services, Inc. holds 71.23K shares, accounting for 2.18% of the total shares.
Tsui (Heung Mei) holds 18.63K shares, accounting for 0.57% of the total shares.
Li (Zhilin) holds 302.76K shares, accounting for 9.28% of the total shares.
Liu (Tao Chengdu) holds 300.00K shares, accounting for 9.20% of the total shares.
Citadel Advisors LLC holds 23.07K shares, accounting for 0.71% of the total shares.
UBS Financial Services, Inc. holds 71.23K shares, accounting for 2.18% of the total shares.
Tsui (Heung Mei) holds 18.63K shares, accounting for 0.57% of the total shares.
What are the top three shareholder types of China Pharma Holdings Inc?
The top three shareholder types of China Pharma Holdings Inc are:
Yang (Yan)
Zhan (Wenlong)
Jianying (Cai)
Yang (Yan)
Zhan (Wenlong)
Jianying (Cai)
How many institutions hold shares of China Pharma Holdings Inc (CPHI)?
As of 2025Q4, 15 institutions hold shares of China Pharma Holdings Inc, with a combined market value of approximately 76.44K, accounting for 2.51% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -1.35%.
What is the biggest source of revenue for China Pharma Holdings Inc?
In FY2025Q2, the Domestic Pharmaceuticals business generated the highest revenue for China Pharma Holdings Inc, amounting to 1.03M and accounting for --% of total revenue.
